Vetter Pharma-Fertigung Launches Major Expansion
Vetter Pharma-Fertigung Launches Major Expansion
June 22, 2005
PharmaManufacturing.com
Vetter Pharma-Fertigung GmbH & Co. KG (Ravensburg, Germany), an international contract manufacturer with a focus on aseptic filling of liquid and lyophilized drugs, on June 21 announced plans for a significant expansion of its production capacity.
Scheduled for completion by the fall of 2006, Vetter's new state-of-the-art facility will increase its production capacity by more than 30 percent and allow Vetter to broaden its product portfolio. The company is presently capable of producing more than 300 million pre-filled syringe systems per year at its various sites.
Vetter's new facility is being built in the vicinity of the existing production lines. Each location operates independently and can be used at all times as a fully operational back-up facility. By duplicating the production lines, Vetter is providing its customers with considerable delivery and process security. For over 15 years, Vetter?s production facilities have been inspected regularly by international regulatory agencies, including the U.S. Food and Drug Administration and the European Medicines Agency (EMEA), as well as its customers.
Vetter Pharma-Fertigung GmbH & Co. KG has been active as an independent pharmaceutical service partner for more than 50 years. Twenty-five years ago, Vetter began focusing on the aseptic production of liquid and lyophilized drugs. In addition to standard injection systems and cartridges, the company also offers its own administration systems, such as the Vetter Lyo-Ject dual-chamber syringe. Vetter currently has more than 127 patents to its name, including solutions to prevent counterfeiting and piracy. The company offers a variety of services through its three branches: Development Service, for product development from manufacturing to launch; Commerical Manufacturing, for start-to-finish manufacturing operations; and Solutions, which specializes in application systems.
Comments: 0
Votes:39